Moderna will host the annual Science and Technology Day on May 17, 2022

CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ: MRNA), a biotechnology company that pioneers RNA (mRNA) therapy and vaccines, today announced it will host a personal Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA .

Modern Science and Technology Day will feature presentations by Stephen Hoge, President, Ph.D. Melisse Moore, Chief Scientific Officer for Scientific Affairs, and Modern Scientists for mRNA and Technical Development Platform with a focus on the company’s latest achievements since its commitment to the basic and applied sciences.

The live webcast will be available under “Events and Presentations” in the Investors section of the Modern website at The replay of the webcast will be archived on the Moderna website one year after the presentation.

About Modern

In the more than 10 years since its inception, Moderna has transformed from a research phase that enhances messenger RNA (mRNA) programs into an enterprise with a diverse clinical portfolio of vaccines and therapies across seven modalities, a broad portfolio of intellectual property in areas including mRNA formulation and lipid nanoparticles, and an integrated production facility that enables rapid clinical and commercial production on a large scale. Moderna maintains alliances with a wide range of domestic and foreign government and commercial associates, which has enabled the search for revolutionary science and a rapid increase in production. Recently, modern capabilities have come together to enable the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Modern mRNA platform is based on continuous advances in basic and applied mRNA science, delivery and production technology, and has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been declared the top employer in the biopharmaceutical industry Science the last seven years. For more information, visit

Modern Contact:

Avalanche Talukdar
Senior Vice President and Head of Investor Relations
[email protected]

SOURCE: Moderna, Inc.

Check out the original version at

Leave a Comment